Will not do any out-licensing in near-term: Wockhardt

Will not do any out-licensing in near-term: Wockhardt Habil Khorakiwala, Founder, Chairman and Group CEO, Wockhardt says US FDA granting a QIDP status to WCK 5222 drug makes it the only company globally to receive this status for its fourth drug.